Neurocrine Biosciences, Inc. NBIX
Analyst Consensus
Price Objectif
Analyst historical
| Analyste | Entreprise | Prix lors de l'analyse | Prix cible | Gain potentiel | Date de publication |
|---|---|---|---|---|---|
| Ashwani Verma | UBS | 137.15 $ | 188 $ | 50.85 % | 05/01/2026 |
| Danielle Brill | Truist Financial | 139.9 $ | 172 $ | 32.10 % | 29/10/2025 |
| Paul Matteis | Stifel Nicolaus | 143.09 $ | 183 $ | 39.91 % | 29/10/2025 |
| Ami Fadia | Needham | 147.38 $ | 184 $ | 36.62 % | 29/10/2025 |
| Akash Tewari | Jefferies | 147.38 $ | 174 $ | 26.62 % | 29/10/2025 |
| Ashwani Verma | UBS | 139.4942 $ | 195 $ | 55.51 % | 09/10/2025 |
| Andrew Fein | H.C. Wainwright | 101.74 $ | 168 $ | 66.26 % | 22/04/2025 |
| Ashwani Verma | UBS | 137.55 $ | 162 $ | 24.45 % | 08/01/2025 |
| Evan David Seigerman | BMO Capital | 120.27 $ | 121 $ | 0.73 % | 31/10/2024 |
| Jay Olson | Oppenheimer | 116.57 $ | 192 $ | 75.43 % | 22/10/2024 |
| Danielle Brill | Raymond James | 111.62 $ | 155 $ | 43.38 % | 10/10/2024 |
| Evan David Seigerman | BMO Capital | 122.29 $ | 128 $ | 5.71 % | 13/09/2024 |
| Carter Gould | Barclays | 120.17 $ | 160 $ | 39.83 % | 09/09/2024 |
| Brian Abrahams | RBC Capital | 123.76 $ | 136 $ | 12.24 % | 29/08/2024 |
| David Amsellem | Piper Sandler | 128.43 $ | 159 $ | 30.57 % | 29/08/2024 |
| Jeffrey Hung | Morgan Stanley | 146.5 $ | 170 $ | 23.50 % | 12/07/2024 |
| Brian Abrahams | RBC Capital | 133.69 $ | 141 $ | 7.31 % | 06/06/2024 |
| Ashwani Verma | UBS | 139.4 $ | 193 $ | 53.60 % | 28/05/2024 |
| Cory Kasimov | Evercore ISI | 136.15 $ | 175 $ | 38.85 % | 13/05/2024 |
| Sumant Kulkarni | Canaccord Genuity | 143.03 $ | 164 $ | 20.97 % | 02/05/2024 |
| Andrew Fein | H.C. Wainwright | 143.03 $ | 160 $ | 16.97 % | 02/05/2024 |
| Mohit Bansal | Wells Fargo | 139.345 $ | 170 $ | 30.66 % | 23/04/2024 |
| Jay Olson | Oppenheimer | 137.74 $ | 200 $ | 62.26 % | 12/03/2024 |
| Brian Skorney | Robert W. Baird | 119.36 $ | 150 $ | 30.64 % | 02/11/2022 |
| Andrew Fein | H.C. Wainwright | 119.36 $ | 140 $ | 20.64 % | 02/11/2022 |
| David Amsellem | Piper Sandler | 119.36 $ | 103 $ | -16.36 % | 02/11/2022 |
| Marc Goodman | SVB Securities | 119.36 $ | 115 $ | -4.36 % | 02/11/2022 |
| Andrew Fein | H.C. Wainwright | 86.52 $ | 140 $ | 53.48 % | 14/02/2022 |
| Marc Goodman | Leerink Partners | 85.53 $ | 100 $ | 14.47 % | 11/02/2022 |
| Brian Skorney | Robert W. Baird | 85.53 $ | 117 $ | 31.47 % | 11/02/2022 |
| Paul Matteis | Stifel Nicolaus | 85.53 $ | 136 $ | 50.47 % | 11/02/2022 |
| Danielle Brill | Raymond James | 85.53 $ | 125 $ | 39.47 % | 11/02/2022 |
| Tazeen Ahmad | Bank of America Securities | 75.51 $ | 127 $ | 51.49 % | 26/01/2022 |
| Carter Gould | Barclays | 72.8 $ | 100 $ | 27.20 % | 20/01/2022 |
| Neena Bitritto-Garg | Citigroup | 84.26 $ | 129 $ | 44.74 % | 08/12/2021 |
| Charles Duncan | Cantor Fitzgerald | 95.58 $ | 123 $ | 27.42 % | 02/11/2021 |
| Joshua Schimmer | Evercore ISI | 95.58 $ | 130 $ | 34.42 % | 02/11/2021 |
| Sumant Kulkarni | Canaccord Genuity | 89.57 $ | 108 $ | 18.43 % | 06/08/2021 |
| Laura Chico | Wedbush | 93.2 $ | 112 $ | 18.80 % | 04/08/2021 |